Selecta and Sobi Report P-III Trial (DISSOLVE I & II) Results of SEL-212 for Chronic Refractory Gout
Shots:
- The P-III trial (DISSOLVE I & II) evaluates 2 dose levels of SEL-212 vs PBO in adult patients. Both trials met its 1EPs i.e., patients who received monthly doses of SEL-212 achieved a response at high & low doses (0.15 & 0.1mg/kg) in the (DISSOLVE I) trial (56% & 48% vs 4% in PBO); 47% & 41% vs 12% in (DISSOLVE II) trial at 6mos.
- At both doses, the response rate in patients aged ≥50yrs was 65% & 47% in (DISSOLVE I) and 48% & 45% in (DISSOLVE II) over 14% in PBO with a 69% reduction in mean SU levels at 0.15mg/kg in (DISSOLVE I) trial
- The therapy showed a favorable safety profile & was well-tolerated across both doses with 3.4% of patients with infusion reactions at high doses. Regulatory submission in the US is expected in H1’24
Ref: Globenewswire | Image: Mynewsdesk
Related News:- Sobi & Selecta Report Results of SEL-212 in P-II COMPARE Study for Chronic Refractory Gou
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
